Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × cediranib × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 4 Gastrointestinal 1 Dermatologic 1

Conditions

Melanoma 4 Uveal Melanoma 2 Rectal Neoplasms 2 Colonic Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms, Male 2 Breast Neoplasms 2 Brain Neoplasms 2 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Oligodendroglioma 1 Neoplasm Metastasis 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Ependymoma 1 Astrocytoma 1

Interventions

pembrolizumab 30 Cyclophosphamide 22 Nivolumab 21 aldesleukin 19 Ipilimumab 19 Interleukin-2 15 fludarabine 14 Specimen Handling 11 fludarabine phosphate 10 Dacarbazine 10 Radiosurgery 9 Magnetic Resonance Spectroscopy 9 Biopsy 9 Temozolomide 8 dabrafenib 5 cemiplimab 5 Vemurafenib 5 Radiotherapy 5 trametinib 4 sargramostim 4 binimetinib 4 avelumab 4 Paclitaxel 4 Cisplatin 4 Bevacizumab 4 lenvatinib 3 encorafenib 3 durvalumab 3 Pemetrexed 3 Lenalidomide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04184518 2020-06-02

CEDUVEAL-M

Grupo Español Multidisciplinar de Melanoma

Phase 2 Withdrawn

Uveal Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡